We are live on ! Find out more

ArriVent BioPharma

AVBP

Market cap $673M

13.64 USD

+1.41

11.53%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

13.52

-0.12

0.88%

1 day

11.53%

5 days

-8.39%

1 month

-9.61%

3 months

-56.01%

6 months

-53.95%

Year to date

-34.42%

1 year

-25.83%

5 years

-31.8%

10 years

-31.8%

About: ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Employees: 77

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 5.6%

Neutral 83.3%

Negative 11.1%

Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference

HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics (Aarvik), an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce important updates to its partnership efforts. Dosing of the first patient in a Phase 1 trial in the US for AV-P138-ADC (ARR-002) was recently announced by Aarvik's research collaboration partner, ArriVent Biopharma, Inc. (ArriVent; Nasdaq: AVBP). AV-P138-ADC (ARR-002) is the first MUTTA™-based ADC.

Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference

Arrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP Investments

New York, New York--(Newsfile Corp. - October 28, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Arrivent BioPharma ("Arrivent" or the "Company") (NASDAQ: AVBP) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?

Arrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP Investments

ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma NASDAQ: AVBP presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in heavily pretreated metastatic colorectal cancer patients during a virtual webinar following an ESMO late-breaking oral presentation.

ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program. To register for the event, click here.

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop

NEW YORK--(BUSINESS WIRE)---- $AVBP #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Arrivent BioPharma (“Arrivent” or the “Company”) (NASDAQ: AVBP) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM'S INVESTIGATION]What Happened?On October 6, 2026, Arrivent disclosed that its Phase 3 FURVENT trial of firmonertinib, the Company'.

ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighting the preclinical and clinical findings supporting its potential, if approved, as the first oral, chemotherapy-free targeted therapy for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC).

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma (“Arrivent” or the “Company”) (NASDAQ: AVBP). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Arrivent securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.

ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors.

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) for ovarian and endometrial cancer.

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

See News Rankings

Price charts implemented using Lightweight Charts™